NCT01617928已完成1 期
A Phase 1 Study of Veliparib (ABT-888) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Solid Tumors
AbbVie (prior sponsor, Abbott)1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2012年5月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Determine the maximum tolerated dose and recommended Phase two dose
研究概览
简要总结
This is a Phase 1 open-label study and consists of 3 treatment groups (dose levels) . Treatment cycles are 3 weeks in duration. The primary objective of this study is to determine the recommended phase two dose (RPTD) of veliparib (ABT-888) when administered in combination with carboplatin and paclitaxel in Japanese subjects with solid tumors. Secondary objectives are to assess pharmacokinetics and to obtain a preliminary efficacy of anti-tumor activity in the subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have histologically or cytologically confirmed malignant solid tumor.
- •Patients who are amenable to standard combination chemotherapy of carboplatin and paclitaxel.
- •Patients should have received less than or equal to 1 prior chemotherapy regimens for advanced stage disease.
- •Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to
- •Patients must have normal organ and marrow function
排除标准
- •Patients who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or the adverse events due to agents administered more than 3 weeks earlier have not recovered to less than grade
- •Known history of allergic reactions to carboplatin or cremophor-paclitaxel.
- •Patients who have previously received a poly(ADP-ribose) polymerase (PARP) inhibitor.
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active systemic infection requiring treatment, symptomatic congestive heart failure, angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- •History of seizure disorder.
- •Hepatitis B surface antigen (HBsAg) positive, Hepatitis C virus (HCV) antibody positive or Human immunodeficiency virus (HIV)-positive patients.
研究组 & 干预措施
veliparib (ABT-888)
Experimental
干预措施: veliparib (ABT-888) (Drug)
veliparib (ABT-888)
Experimental
干预措施: carboplatin (Drug)
veliparib (ABT-888)
Experimental
干预措施: paclitaxel (Drug)
结局指标
主要结局
Determine the maximum tolerated dose and recommended Phase two dose
时间窗: During the first cycle (21 days from first dose of veliparib)
次要结局
- Safety assessment; Adverse event monitoring(From date of first dose of veliparib until 30 days after last dose of veliparib (up to 6 cycles))
- Pharmacokinetics; Area Under the Curve (AUC), Maximum observed plasma concentration (Cmax) and Time to Cmax (Tmax) of carboplatin when administered in combination with veliparib (ABT-888) and paclitaxel(Six timepoints on Day 3 of first cycle (21 days))
- Safety assessment; Change from Baseline in Electrocardiogram (ECG)(Day 8 of first cycle (21 days))
- Pharmacokinetics; Area Under the Curve (AUC), Maximum observed plasma concentration (Cmax) and Time to Cmax (Tmax) of veliparib (ABT-888)(Eight timepoints on Day 1 of first cycle (21 days))
- Pharmacokinetics; Area Under the Curve (AUC), Maximum observed plasma concentration (Cmax) and Time to Cmax (Tmax) of veliparib (ABT-888) when administered in combination with carboplatin and paclitaxel(Eight timepoints on Day 3 of first cycle (21 days))
- Preliminary tumor response(From date of first dose of veliparib until the date of first documented progression or date of death from any cause, whichever come first, assessed up to 6 cycles.)
- Safety assessment; Physical exam including vital signs(From date of first dose of veliparib until 30 days after last dose of veliparib (up to 6 cycles))
- Pharmacokinetics; Area Under the Curve (AUC), Maximum observed plasma concentration (Cmax) and Time to Cmax (Tmax) of paclitaxel when administered in combination with veliparib (ABT-888) and carboplatin(Eight timepoints on Day 3 of first cycle (21 days))
- Safety assessment; Clinical lab testings(From date of first dose of veliparib until 30 days after last dose of veliparib (up to 6 cycles))
研究者
研究点 (1)
Loading locations...
相似试验
撤回
1 期
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine TumorFunctional Pancreatic Neuroendocrine TumorMalignant SomatostatinomaMetastatic Adrenal Gland PheochromocytomaMetastatic Carcinoid TumorMultiple Endocrine Neoplasia Type 2AMultiple Endocrine Neoplasia Type 2BMultiple Endocrine Neoplasia Type 1Merkel Cell CarcinomaNon-Functional Pancreatic Neuroendocrine TumorPancreatic GlucagonomaPancreatic InsulinomaRecurrent Adrenal Cortex CarcinomaNeuroendocrine NeoplasmRecurrent Adrenal Gland PheochromocytomaRecurrent Merkel Cell CarcinomaSomatostatin-Producing Neuroendocrine TumorStage III Adrenal Cortex CarcinomaStage III Thyroid Gland Medullary CarcinomaStage IIIA Merkel Cell CarcinomaStage IIIB Merkel Cell CarcinomaStage IV Adrenal Cortex CarcinomaStage IV Merkel Cell CarcinomaStage IVA Thyroid Gland Medullary CarcinomaStage IVB Thyroid Gland Medullary CarcinomaStage IVC Thyroid Gland Medullary CarcinomaThymic Carcinoid TumorVIP-Producing Neuroendocrine TumorWell Differentiated Adrenal Cortex CarcinomaZollinger Ellison SyndromeNCT02831179Vanderbilt-Ingram Cancer Center
已完成
1 期
Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal CancerAdult Solid NeoplasmPeritoneal CarcinomatosisRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaNCT01264432National Cancer Institute (NCI)34
未知
1 期
A Phase 1 Study of veliparib (ABT-888) in Combination with Carboplatin/Paclitaxel in Japanese Subjects with solid tumorsSolid tumorsJPRN-jRCT2080221796AbbVie GK12
已完成
1 期
A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid TumorsAdvanced Solid TumorsNCT01063816AbbVie (prior sponsor, Abbott)79
终止
1 期
Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung CancerAdvanced Adult Primary Liver CancerLocalized Unresectable Adult Primary Liver CancerMetastatic Transitional Cell Cancer of the Renal Pelvis and UreterRegional Transitional Cell Cancer of the Renal Pelvis and UreterStage III Bladder CancerStage III Pancreatic CancerStage IIIA Non-small Cell Lung CancerStage IIIB Non-small Cell Lung CancerStage IV Bladder CancerStage IV Non-small Cell Lung CancerStage IV Pancreatic CancerTransitional Cell Carcinoma of the BladderUnresectable Extrahepatic Bile Duct CancerUnresectable Gallbladder CancerNCT01282333National Cancer Institute (NCI)44